Semaglutide
Semaglutide (GLP-1 Receptor Agonist)
Also known as: Ozempic, Wegovy, Rybelsus
Prompted by Jack Butcher (Visualize Value) · AI-authored by Claude · Research-sourced
FDA-approved GLP-1 agonist (Ozempic/Wegovy) that produces 15% average body weight loss in clinical trials. The most extensively studied weight-loss peptide therapeutic, with proven cardiovascular benefits.
Quick Facts
FDA-approved as Ozempic (type 2 diabetes) and Wegovy (chronic weight management). Rybelsus approved for oral use in diabetes.
Overview
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics the effects of the naturally occurring incretin hormone GLP-1. It is one of the most extensively studied and commercially successful peptide therapeutics in modern medicine.
Originally developed for type 2 diabetes management, semaglutide gained widespread attention for its significant effects on weight loss. The STEP clinical trial program demonstrated average weight reductions of 15–17% of body weight at the 2.4 mg weekly dose.
Semaglutide has a remarkably long half-life of approximately 7 days due to structural modifications including a C-18 fatty acid chain and amino acid substitutions that increase albumin binding and resistance to DPP-4 degradation.
Mechanism of Action
Semaglutide activates the GLP-1 receptor, a G protein-coupled receptor expressed in pancreatic beta cells, the gastrointestinal tract, heart, kidneys, and multiple brain regions including the hypothalamus and brainstem.
In the pancreas, GLP-1 receptor activation stimulates glucose-dependent insulin secretion and suppresses glucagon release, improving glycemic control. Critically, this is glucose-dependent — insulin release only occurs when blood glucose is elevated, reducing hypoglycemia risk.
In the brain, semaglutide acts on appetite-regulating centers in the hypothalamus and brainstem. It reduces hunger, increases satiety, and appears to modify food reward pathways. Neuroimaging studies show reduced activation of brain regions associated with food cravings.
Semaglutide also slows gastric emptying, contributing to post-meal satiety. It has demonstrated direct cardiovascular benefits including reduced arterial inflammation and improved endothelial function, independent of weight loss.
Research Summary
Semaglutide has one of the most robust clinical evidence bases of any peptide therapeutic. The SUSTAIN trial program (1–10) established efficacy in type 2 diabetes with superior HbA1c reduction compared to other diabetes medications.
The STEP trial program (1–5) demonstrated transformative weight loss results. STEP 1 showed 14.9% mean weight loss vs. 2.4% with placebo over 68 weeks. STEP 2 in diabetic patients showed 9.6% weight loss. STEP 3 combined with intensive behavioral therapy achieved 16% weight loss.
The SELECT cardiovascular outcomes trial demonstrated a 20% reduction in major adverse cardiovascular events (MACE) in overweight/obese adults without diabetes, leading to expanded cardiovascular indications.
Emerging research explores semaglutide for NAFLD/NASH (fatty liver disease), Alzheimer's disease, addiction (alcohol and substance use disorders), and polycystic kidney disease. The FLOW trial showed significant renal benefits.
Key References
Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)
Wilding JPH, et al. · New England Journal of Medicine (2021) · 10.1056/NEJMoa2032183
Landmark trial demonstrating 14.9% mean body weight reduction with semaglutide 2.4 mg weekly vs. 2.4% with placebo over 68 weeks in 1,961 adults.
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6)
Marso SP, et al. · New England Journal of Medicine (2016) · 10.1056/NEJMoa1607141
Cardiovascular outcomes trial showing 26% reduction in MACE with semaglutide in type 2 diabetes patients over 2 years.
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT)
Lincoff AM, et al. · New England Journal of Medicine (2023) · 10.1056/NEJMoa2307563
SELECT trial demonstrated 20% reduction in major cardiovascular events with semaglutide in overweight/obese adults without diabetes.
Effect of Semaglutide on the Progression of Renal Impairment (FLOW)
Perkovic V, et al. · New England Journal of Medicine (2024) · 10.1056/NEJMoa2403347
FLOW trial demonstrated significant reduction in kidney disease progression in patients with type 2 diabetes and chronic kidney disease.
Protocols
Weight management (FDA-approved)
Dose escalation over 16–20 weeks: 0.25 mg × 4 weeks → 0.5 mg × 4 weeks → 1.0 mg × 4 weeks → 1.7 mg × 4 weeks → 2.4 mg maintenance.
Type 2 diabetes (FDA-approved)
Start at 0.25 mg for 4 weeks, then 0.5 mg. May increase to 1.0 mg and then 2.0 mg based on glycemic response.
Oral formulation (diabetes)
Take on empty stomach with no more than 4 oz of water, at least 30 minutes before food. Dose escalation: 3 mg × 30 days → 7 mg → 14 mg.
Side Effects & Safety
| Frequency | Effect |
|---|---|
| common | Nausea Most common side effect, affecting 20–44% of users. Usually improves over weeks. Dose escalation helps mitigate. |
| common | Vomiting Affects approximately 15–25% of users. More common during dose escalation. |
| common | Diarrhea Affects 15–30% of users. Usually transient. |
| common | Constipation Affects 10–24% of users. |
| uncommon | Injection site reactions Redness, itching, or pain at injection site. |
| rare | Pancreatitis Acute pancreatitis has been reported. Discontinue if suspected. |
| uncommon | Gallbladder events Cholelithiasis and cholecystitis reported at higher rates than placebo. |
Contraindications
- —Personal or family history of medullary thyroid carcinoma (MTC)
- —Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- —Known hypersensitivity to semaglutide
- —History of pancreatitis (use with caution)
- —Pregnancy or planning to become pregnant (discontinue at least 2 months before)
Interactions
- —Delays gastric emptying — may affect absorption of oral medications
- —May increase risk of hypoglycemia when combined with insulin or sulfonylureas
- —Oral contraceptives may have reduced efficacy due to delayed gastric emptying
Reconstitution & Storage
Related Peptides
Sometimes discussed alongside Tirzepatide (dual GIP/GLP-1 agonist), which has shown even greater weight loss in head-to-head trials. AOD-9604 targets different fat-loss pathways.